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The serine-threonine protein kinase Akt2, also known as PKBb, has been shown to regulate glucose and lipid
metabolism in animal models. In a recent study published in Science, Hussain et al. (2011) report that in
human subjects an activating mutation of Akt2 leads to hypoglycemia and, unexpectedly, asymmetric
overgrowth.There is little doubt that the practice
of medicine has benefited from the
use of preclinical models for transla-
tional research. Laboratory animals
have allowed the elucidation of basic
molecular and cellular pathways, and
have proved particularly valuable for
the study of integrative physiology. In
addition, generation of invertebrate and
vertebrate models that approximate
human diseases have provided regularly
used reagents for uncovering the patho-
physiology of those diseases. Nonethe-
less, in recent years there has been
growing skepticism that animals, and in
particular mice, faithfully mimic human
biology such that findings in rodents
cannot reliably be applied to humans.
Needless to say, this potential problem
is compounded when the animal re-
search is performed in models of human
diseases, which are often imperfect. In
most cases, however, it is difficult to
discern whether apparent dissimilarities
between mouse and man/woman are
due to differences in the underlying
biology or in the experimental ap-
proaches utilized to obtain the data.
Thus, the confirmation in humans of
pathways analogous to those in mice is
of great significance; fortunately, such
events have become common with the
increasing frequency of identification of
human gene mutations and their conse-
quences. Now, in a recent issue of
Science, Hussain et al. have reported
an activating mutation of the serine-thre-
onine protein kinase AKT2 in human
subjects (Hussain et al., 2011). These
individuals exhibit profound hypogly-
cemia, as would have been predicted
based on extensive experimentation in
mouse models and tissue culture cells;
however, they also have unexpected
asymmetric overgrowth.722 Cell Metabolism 14, December 7, 2011 ªThe insulin/IGF1 signaling pathway is
critical to the regulation of metabolism
and organismal growth and to the
development of cancer in a number of
model organisms including mouse and
Drosophila melanogaster. The identifica-
tion of mutations in several components
in this pathway in patients with cellular
growth abnormalities like Cowden syn-
drome and tuberous sclerosis has
confirmed similarity in the regulation
of growth between mice and people
(Hennessy et al., 2005). A signaling pro-
tein that mediates the growth-promoting
effects of IGF1 and many of the metabolic
actions of insulin in mice is the protein
kinase Akt, also known as protein kinase
B (PKB) (Gonzalez and McGraw, 2009).
Three AKT genes, AKT1/PKBa, AKT
2/PKBb, andAKT3/PKBg, encodea family
of paralogous kinases in both humans
and mice. Experiments in mice using iso-
form-specific gene recombination sug-
gest that Akt1 primarily regulates growth,
whereas Akt2 is more important to the
control of glucose and lipid metabolism,
though clearly these functions sometimes
overlap. A number of human tumors
are associated with amplification of or
activating mutations in the AKT1 gene,
suggesting a conserved function for
the encoded protein in growth control in
humans (Hennessy et al., 2005). One
of these changes is a lysine substitu-
tion for glutamic acid at the highly
conserved amino acid 17 (E17K) of the
lipid-binding pleckstrin homology (PH)
domain, which results in constitutive
membrane location (Carpten et al.,
2007). The presence of the same substitu-
tion but as a somatic mosaic mutation
in humans leads to Proteus syndrome,
which features overgrowth of skin, con-
nective tissue, brain, and other tissues
(Lindhurst et al., 2011). These reports2011 Elsevier Inc.support the rodent studies that implicate
Akt1 as the key regulator of cell growth
and proliferation.
In contrast to AKT1 mutations, few
spontaneous mutations have been identi-
fied that test whether Akt2’s importance
to the control of carbohydrate and lipid
metabolism in mice is conserved in
humans. Two severely insulin-resistant
patients have been reported to be hetero-
zygous for a putatively dominant inhibi-
tory R274Hmutation in the kinase domain
ofAKT2, which replicates the diabetic and
insulin-resistant phenotype of mice with
germline deletion of Akt2 (Cho et al.,
2001; George et al., 2004). However,
unlike mice, in which loss of Akt2 protects
against triglyceride accumulation in liver
and increased circulating triglycerides,
patients with the R274H mutation have
hyperlipidemia and steatosis, raising the
possibility that not all aspects of the
regulation of metabolism are conserved
between mice and humans (Leavens and
Birnbaum, 2011; Semple et al., 2009).
This interpretation must be qualified by
the risk that the distinct phenotypes
between mouse and man/woman might
have resulted from an associated muta-
tion(s) at a locus other than AKT2,
a complication that must be considered,
particularly when the human cohort is
small and limited to a single family.
Now the same Cambridge group that
reported the loss of function mutation of
AKT2 has found an alteration in AKT2
that, as for AKT1 as described above,
substitutes a lysine for a glutamic acid in
the PH domain leading to constitutive
activation (Hussain et al., 2011). As would
have been predicted form the mouse
studies, patients carrying the Akt2 E17K
mutation display all the features of hyper-
insulinemia, including severe, refractory
hypoglycemia and low levels of serum
Figure 1. Summary of Insulin’s Effects on Glucose and Lipids
In mice, there are abundant data supporting the idea that insulin produces
many effects on metabolism by activating Akt2. These include increased
glucose uptake into muscle and fat and decreased production from liver.
The discovery of an activating mutation in Akt2 that leads to the same pheno-
type in humans as hyperinsulinemia lends strong support to the idea that this
pathway is conserved between man and mice.
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Previewsketone bodies and free fatty
acids, but with undetectable
plasma insulin (see Figure 1).
These data are most consis-
tent with activation of the
insulin signaling pathway at
physiological target tissues,
most notably liver and skel-
etal muscle, which are en-
riched in expression of the
Akt2 isoform (Cho et al.,
2001). Unfortunately, Hussain
et al. (2011) were unable to
obtain more detailed data
about metabolic pathways in
these patients, but after all,
the limitations of human
research are precisely why
we invest so much time and
energy in animal models. Ofnote, the patients carrying the AKT2 E17K
mutation developed early obesity, which
is at least consistent with the primary
positive role forAkt2 in denovo lipogenesis
and lipid accumulation in murine liver
(Leavens and Birnbaum, 2011).
A surprising feature of the phenotype
described by Hussain et al. in the AKT2
E17K individuals is their striking asym-
metric left-sided overgrowth (Hussain
et al., 2011). Patients carrying the AKT1
mutation also show hypertrophy, but
they are mosaic for the activation muta-
tion (Lindhurst et al., 2011). Congenital
hemihypertrophy is observed as part
of several human disorders, including
Beckwith-Wiedemann syndrome (BWS),
a rare disease caused by a defect in an
imprinted region of chromosome 11. TheIGF2 gene lies within this interval, and its
product, which can activate Akt through
both the IGF1 and insulin receptors, is
frequently increased in BWS. In fact,
infants with BWS often demonstrate
hypoglycemia, though it is not clear
whether this also is a result of increased
IGF2.
In summary, the mutations identified by
Hussain et al. (2011) provide a striking and
convincing confirmation of the impor-
tance of Akt2 in transmitting the signal
from insulin for increased glucose uptake
and/or suppression of hepatic glucose
output. As a bonus, this discovery also
adds considerable weight to the notion
that asymmetric overgrowth syndromes
also can be attributed to inappropriate
activity of Akt.Cell Metabolism 14, December 7ACKNOWLEDGMENTS
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